| 14.03 0.95 (7.26%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 18.69 | 1-year : | 21.23 |
| Resists | First : | 16 | Second : | 18.18 |
| Pivot price | 13.8  |
|||
| Supports | First : | 12.48 | Second : | 10.39 |
| MAs | MA(5) : | 13.46 |
MA(20) : | 14.46 |
| MA(100) : | 13.59 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 28.7 |
D(3) : | 18.2 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 18.18 | Low : | 11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GENB ] has closed below upper band by 36.3%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 14.32 - 14.4 | 14.4 - 14.47 |
| Low: | 12.91 - 13.01 | 13.01 - 13.1 |
| Close: | 13.88 - 14.03 | 14.03 - 14.17 |
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
Thu, 30 Jul 2026
Top Generate Biomedicines (GENB) Competitors 2026 - MarketBeat
Mon, 27 Jul 2026
Generate Biomedicines, Inc. Revenue Breakdown – NASDAQ:GENB - TradingView
Thu, 23 Jul 2026
Generate Biomedicines: Post Mega-Money IPO, Caution Is Warranted (NASDAQ:GENB) - Seeking Alpha
Wed, 22 Jul 2026
If You Invested $1,000 in Generate Biomedicines (GENB) - stocktitan.net
Tue, 23 Jun 2026
Morgan Stanley Maintains an Overweight Rating on Generate Biomedicines, Inc. (GENB) - Yahoo Finance
Mon, 01 Jun 2026
Assessing Generate Biomedicines (GENB) Valuation As Losses Mount And Price To Book Sits At 3.3x - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 128 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 14 (%) |
| Held by Institutions | 76 (%) |
| Shares Short | 6,990 (K) |
| Shares Short P.Month | 4,550 (K) |
| EPS | -2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.01 |
| Profit Margin | 0 % |
| Operating Margin | -887.5 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -18.2 % |
| Gross Profit (p.s.) | -1.61 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -1.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -228 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -6.78 |
| PEG Ratio | 0 |
| Price to Book value | 3.49 |
| Price to Sales | 59.35 |
| Price to Cash Flow | -7.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|